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Abstract In Europe, the introduction of monovalent menin-
gococcal serogroup C (MenC) conjugate vaccines has
resulted in a significant decline in MenC invasive disease.
However, given the potential for strain evolution and in-
creasing travel to areas of high endemicity, protection
against additional serogroups is needed. In this study, the
immunogenicity, measured by a serum bactericidal activity
assay using rabbit complement (rSBA), and the safety of a
quadrivalent meningococcal serogroups A, C, W-135 and Y
tetanus toxoid conjugate vaccine (MenACWY-TT) were
compared to that of a licensed monovalent MenC conjugate
vaccine (MenC-CRM197) in children 2–10 years of age.
Children were randomised (3:1) to receive a single dose of
either MenACWY-TT or MenC-CRM197. Non-inferiority of
the immunogenicity of MenACWY-TT versus MenC-
CRM197 in terms of rSBA-MenC vaccine response was
demonstrated. Exploratory analyses suggested that rSBA-
MenC geometric mean titres adjusted for pre-vaccination
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titres were lower in children vaccinated with MenACWY-
TT compared to MenC-CRM197. Nevertheless, at 1 month
post-vaccination, ≥99.3 % of the children who received
MenACWY-TT had rSBA titres ≥1:128 for each of the four
vaccine serogroups, which is the more conservative corre-
late of protection. The reactogenicity and safety profile of
MenACWY-TT was clinically acceptable and no serious
adverse events considered related to vaccination were
reported throughout the study. Conclusion: When adminis-
tered to European school-age children, MenACWY-TT has
a clinically acceptable safety profile and, when compared
with MenC-CRM197, the potential to broaden protection
against meningococcal disease caused by serogroups A,
W-135 and Y while maintaining protection against MenC.
This study has been registered at www.clinicaltrials.gov
NCT00674583.
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Introduction
Neisseria meningitidis is an important cause of invasive
bacterial infections, such as meningitis and sepsis, which
are major public health concerns throughout the world [18,
24, 41]. Although the incidence of meningococcal disease is
highest in infants, children are also at risk, particularly if
they travel to areas of high endemicity. The mean annual
incidence of invasive meningococcal disease was 0.71 per
100,000 inhabitants in Germany between 2002 and 2010
and varied between 0.9 and 1.5 cases per 100,000 inhab-
itants in France during the past 10 years [26, 39]. Globally,
six serogroups (MenA, MenB, MenC, MenW-135, MenY
and MenX) are responsible for most cases of meningococcal
disease [23, 24, 41, 49, 50]. In Europe, MenB and MenC are
the most prevalent serogroups, although diseases caused by
MenA, MenW-135 and MenY have also been reported in
some European countries [2, 6, 22, 51, 52, 54, 55]. In
Germany, the incidence of invasive meningococcal disease
caused by MenB and MenC decreased between 2002 and
2010 from 0.63 to 0.32 cases and from 0.26 to 0.10 cases
per 100,000 inhabitants younger than 25 years of age, re-
spectively [26]. In France, invasive meningococcal disease
cases were also mainly due to MenB and MenC during the
past decade (65 and 27 %, respectively) [39].
Prevention of meningococcal disease by vaccination is
the best control strategy, and the development of broadly
effective vaccines is a public health priority [23, 49]. To
overcome the limitations of meningococcal plain polysac-
charide vaccines, which are poorly immunogenic in young
children, do not induce immune memory, do not reduce
mucosal carriage and do not confer herd immunity, menin-
gococcal capsular polysaccharides were covalently bound to
carrier proteins in conjugate vaccines [19, 23, 25, 34, 38].
Monovalent MenC conjugate vaccines are licensed for use
in children from 2 months of age in Europe [10, 13, 33, 35,
43, 53], children older than 1 year of age in Australia [45],
and children between 2 months and 5 years of age, adoles-
cents, and adults in Canada [5, 31]. Routine MenC vacci-
nation was introduced in the national childhood vaccination
schedule for children 12–24 months of age in Germany in
2006 and in France in 2010 [15, 26]. Of note, the introduc-
tion of monovalent MenC conjugate vaccines into routine
vaccination schedules in Europe since 2006 has led to a ten-
fold drop in the incidence of MenC disease [17]. In the
current study, children 2–10 years of age were vaccinated
in 2008, and an exclusion criterion required that no previous
meningococcal conjugate vaccine had been administered;
therefore, this study did not interfere with either national
vaccination programme.
Given the potential strain evolution and increasing global
travel to areas of high endemicity, vaccines offering broader
protection are needed. A quadrivalent MenA, MenC,
MenW-135 and MenY conjugate vaccine using diphtheria
toxoid as carrier protein (Menactra™, Sanofi Pasteur) has
been licensed in the USA for use in individuals between 11
and 55 years of age since 2005, in children between 2 and
10 years of age in 2007, and in toddlers between 9 and
23 months of age in 2011 [30, 40, 56]. Another quadrivalent
meningococcal conjugate vaccine using a mutant diphtheria
toxoid as carrier protein (MenACWY-CRM197; Menveo™,
Novartis) has been authorised since 2010–2011 for active
immunisation of individuals from 2 years of age in the
European Union and Australia and between 2 and 55 years
of age in Canada and the USA [7, 27, 57]. Beside these
quadrivalent vaccines, a monovalent MenA conjugate vac-
cine (MenA-TT, MenAfriVac™, Serum Institute of India)
has been specifically developed for Africa. MenA accounts
for about 80–85 % of the cases in the ‘Meningitis Belt’, a
region covering 25 countries in sub-Saharan Africa [48].
Finally, a combination Haemophilus influenzae type b–
Neisseria meningitidis serogroups C and Y conjugate vac-
cine (Hib-MenCY-TT, MenHibrix™, GlaxoSmithKline
Vaccines) was licensed for use in US infants [11].
In addition, a quadrivalent MenA, MenC, MenW-135
and MenY tetanus toxoid (TT) conjugate vaccine (Men-
ACWY-TT; Nimenrix™, GlaxoSmithKline Vaccines) has
been developed and recently approved by the European
Medicines Agency for the active immunisation of individu-
als older than 12 months of age [16]. Non-inferiority of
MenACWY-TT compared to a licensed quadrivalent plain
polysaccharide vaccine was shown in a previous study con-
ducted in children 2–10 years of age [37]. Since monovalent
MenC conjugate vaccines are also licensed in school-age
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children, this study was designed to assess immunological
non-inferiority of MenACWY-TT versus a commonly used
monovalent MenC conjugate vaccine (MenC-CRM197;
Menjugate™, Novartis). In addition, the immunogenicity




This study was a phase III, open, randomised, controlled
trial conducted in 20 centres in Germany and 11 centres in
France between May 2008 and January 2009. The study was
conducted in accordance with the guidelines for Good Clin-
ical Practice, all applicable regulatory requirements and the
Declaration of Helsinki. The protocol and associated docu-
ments were reviewed and approved by local ethics commit-
tees. Written informed consent was obtained from the
parents/guardians of children prior to the performance of
any study specific procedures. In Germany, informed
assents were obtained from the children who were able to
understand and sign the informed assent form according to
the investigators’ discretion. In France, parents/legally au-
thorized representatives signed the informed consent form,
with provision of study information to the subject. Informed
consent/assent procedures were aligned with country stand-
ards and were approved by the relevant ethics committee.
Healthy children were enrolled in two age strata: 2–
5 years and 6–10 years of age. Within each age stratum,
children were randomised into two parallel groups to receive
a single dose of either MenACWY-TT (ACWY-TT group)
or MenC-CRM197 (MenC-CRM group). Blood samples
were collected from all children at pre-vaccination (month
0) and at 1 month post-vaccination (month 1). This active
vaccination phase was followed by an extended safety
follow-up phase up to 6 months post-vaccination (month 6).
Treatment allocation at the investigator site was per-
formed using a central, web-based randomisation system.
The randomisation algorithm (block size of four) included a
minimisation procedure to ensure balanced allocation be-
tween groups at individual centres and in the two age strata.
The study was open in design because the vials containing
the study vaccines differed in appearance. This study has
been registered at www.clinicaltrials.gov NCT00674583. A
summary of the protocol is available at http://www.
gsk-clinicalstudyregister.com (GSK study ID 111414).
Study objectives
The primary objective was to demonstrate the non-
inferiority of MenACWY-TT versus MenC-CRM197 in
terms of vaccine response to MenC measured with a serum
bactericidal activity assay using rabbit complement (rSBA)
in children 2–10 years of age. Non-inferiority was shown if
the lower limit (LL) of the two-sided standardised asymp-
totic 95 % confidence interval (CI) for the group difference
(ACWY-TT group minus MenC-CRM group) in the percen-
tages of children with rSBA-MenC vaccine response at
month 1 was greater than or equal to −10 %.
The secondary objectives included the evaluation of the
immunogenicity of MenACWY-TT to MenA, MenW-135
and MenY at month 1; the comparison of the immunogenic-
ity of MenACWY-TT and MenC-CRM in terms of percen-
tages of children with rSBA-MenC titres above pre-defined
thresholds and rSBA-MenC geometric mean titres (GMTs);
and the evaluation of the reactogenicity and safety profiles
of both vaccines throughout the study.
Study participants
Participants were healthy boys or girls between 2 and
10 years of age at the time of vaccination, who had com-
pleted routine childhood vaccination to the best of their
parents/guardians knowledge.
Children who were immunosuppressed from any cause,
had a history of meningococcal disease, had previously
received a meningococcal conjugate vaccine at any time,
had had previous vaccination with a meningococcal poly-
saccharide vaccine (for participants younger than 6 years of
age) or within the last 5 years (for participants 6 years of age
and older), or had previously received immunoglobulins or
blood products within 3 months preceding the study were
excluded from the trial.
Vaccines
One 0.5-mL dose of MenACWY-TT contained 5 μg of each
meningococcal serogroup polysaccharide (MenA, MenC,
MenW-135 and MenY) conjugated to TT (approximately
44μg in total). The lyophilised vaccine was reconstituted with
saline. The licensed MenC-CRM197 vaccine (Menjugate™,
Novartis) comprised 10 μg of MenC polysaccharide conju-
gated to CRM197 (12.5 to 25 μg) adsorbed onto aluminium
hydroxide (0.3–0.4 mg). The vaccines were administered
intramuscularly into the non-dominant deltoid or thigh as
age appropriate.
Immunogenicity assessment
Immunogenicity to all four meningococcal polysaccharides
was assessed with an rSBA assay [1, 36], which was per-
formed as previously described [4]. The cut-off of the assay
was a dilution titre of 1:8, which is considered a surrogate
marker of protection for rSBA-MenC [9] and has been
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extended to the other serogroups [12]. In addition, antibody
titres were also measured using a threshold of 1:128, which
is the more conservative correlate of protection [8]. An
rSBA vaccine response was defined as an rSBA titre of at
least 1:32 in initially seronegative children (i.e. rSBA titre
<1:8) and as a four-fold increase in titre from pre- to post-
vaccination in initially seropositive children (i.e. rSBA titre
≥1:8). All immunological assays were performed at Glax-
oSmithKline’ laboratories (Rixensart, Belgium).
Safety and reactogenicity assessment
The occurrence of solicited local symptoms at the injection
site (pain, redness and swelling in both age strata) and of
solicited general symptoms (drowsiness, fever [oral temper-
ature ≥37.5 °C], irritability and loss of appetite in the 2–
5 years age stratum, and fatigue, fever, gastro-intestinal
symptoms and headache in the 6–10 years age stratum)
was recorded up to 4 days after vaccination by the parents
or guardians on a written diary card. Unsolicited adverse
events (AEs) were recorded on the diary cards for a period
of 31 days after vaccination. These events were then tran-
scribed by the investigator into an electronic case report
form.
The intensity of each symptom was graded on a three-
level scale. In the 2–5 years age stratum, redness and swell-
ing were of grade 3 intensity if their diameter was >30 mm,
pain if the child cried when the limb was moved or if the
limb was spontaneously painful and loss of appetite if the
child did not eat at all. In the 6–10 years age stratum,
redness and swelling were of grade 3 intensity if their
diameter was >50 mm. In both age strata, grade 3 fever
was defined as oral temperature >39.5 °C. All other symp-
toms of grade 3 intensity were defined as symptoms pre-
venting normal activity.
Serious adverse events (SAEs), AEs of specific interest
(new onset of chronic illnesses, rashes and AEs resulting in
emergency room visits) were reported during 6 months post-
vaccination. All solicited local (injection site) reactions were
considered causally related to vaccination. The relationship
to vaccination of all other symptoms was assessed by the
investigator.
Statistical analyses
With a target sample size of 400 children (300 children in
the ACWY-TT group and 100 children in the MenC-CRM
group), the power to meet the primary objective of this study
was at least 85.6 %.
The total vaccinated cohort, on which the primary safety
analyses were performed, included all vaccinated children.
The primary analysis of immunogenicity was performed on
the according to protocol (ATP) cohort for immunogenicity,
which included all the children meeting the eligibility crite-
ria, complying with the protocol-defined procedures, with
no elimination criteria during the study, and for whom data
concerning immunogenicity endpoints were available for at
least one study vaccine antigen. While immunogenicity and
unsolicited symptoms were evaluated on the entire study
population, the safety evaluation for solicited symptoms was
performed separately on the 2–5 years and 6–10 years age
strata because the nature of the solicited general symptoms
and the severity grading of the solicited local symptoms
differed.
Percentages of children with antibody titres above the
proposed cut-offs, vaccine response rates, and GMTs for
the four serogroups were calculated in each treatment group
with 95 % CIs. The GMTs were calculated by taking the
anti-log of the mean of the log10 titre transformations. An-
tibody titres below the cut-off of the assay were given an
arbitrary value of half the cut-off for the purpose of GMT
calculation. The distribution of titres was also evaluated
using reverse cumulative curves for each meningococcal
serogroup.
Exploratory analyses compared immune responses to the
four serogroups between the ACWY-TT and the MenC-
CRM groups. The two groups were considered statistically
significantly different if the standardised asymptotic 95 %
CI for the difference in rates (percentages of children with
titres above proposed cut-offs or with vaccine response)
between the two vaccine groups did not contain the value
‘0’ or if the 95 % CI for the GMT ratio between the two
groups did not contain the value ‘1’. The GMT ratios were
computed by an analysis of covariance model on the log10
transformation of the titres using the pre-vaccination log10
transformation of the titres, the age strata and the vaccine
group as covariates. No adjustment for multiplicity of sec-
ondary endpoints was made, and significant results from the
exploratory analyses should be interpreted with caution.
The percentages of children reporting each solicited local
and general (any and grade 3) symptom were tabulated per
age strata with exact 95 % CIs. The percentages of children
reporting unsolicited AEs (any and grade 3) were tabulated
overall with exact 95 % CIs. SAEs, AEs of specific interest
and withdrawals due to AEs were described in detail.
The statistical analyses were performed using the SAS®




A total of 414 children were enrolled and vaccinated in this
study (311 in the ACWY-TT group and 103 in the MenC-
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CRM group) (Fig. 1). All the children completed the active
vaccination phase of the study, and 413 of them completed
the extended safety follow-up phase. The ATP cohort for
immunogenicity included 296 children in the ACWY-TT
group and 99 children in the MenC-CRM group. The two
treatments groups were comparable in terms of demographic
characteristics (Table 1).
Immunogenicity
The pre-defined criterion assessing the primary immunoge-
nicity objective of non-inferiority was reached; MenACWY-
TT was shown to be non-inferior to MenC-CRM197 as the
LL of the two-sided standardised asymptotic 95 % CI for the
group difference (ACWY-TT group minus MenC-CRM
group) in the percentage of children with rSBA-MenC vac-
cine response was −5.25 % (Table 2). Vaccine response rates
for rSBA-MenC were 94.8 and 95.7 % in the ACWY-TT
and the MenC-CRM groups, respectively.
At month 1, 99.3 % of the children who received
MenACWY-TT had rSBA-MenC titres ≥1:128 compared with
100 % of the children who received MenC-CRM197 (Table 3).
The rSBA-MenC GMTs increased 123-fold from pre- to post-
vaccination in the ACWY-TT group versus 273-fold in the
MenC-CRM group (Tables 3, also illustrated in Fig. 2). Ex-
ploratory analyses did not detect any statistically significant
difference between the two groups in terms of percentages of
children with rSBA-MenC titres ≥1:8 and ≥1:128 but sug-
gested that rSBA-MenC GMTs adjusted for pre-vaccination
measurements and age-strata were statistically significantly
lower in the ACWY-TT group than in the MenC-CRM group.
In the ACWY-TT group, vaccine response rates, percen-
tages of children with rSBA titres ≥1:8 and percentages of
children with rSBA titres ≥1:128 for each of the serogroups
were at least 94.7, 99.7 and 99.3 %, respectively (Tables 2
and 3). rSBA GMTs for the four serogroups increased
between 54-fold (rSBA-MenY) and 198-fold (rSBA-MenA)
from pre- to post-vaccination in the children who received
MenACWY-TT (Table 2, also illustrated in Fig. 2).
Safety
In the 2–5 years age stratum, redness was the most common
solicited local symptom and was reported in 57/162 children
(35.2 %) in the ACWY-TT group and 21/53 children
(39.6 %) in the MenC-CRM group during the 4-day post-
vaccination follow-up period (Fig. 3a). Redness was also the
most frequently reported grade 3 solicited local symptom
and was reported in 11/162 children (6.8 %) and 8/53
children (15.1 %) in the ACWY-TT and the MenC-CRM
groups, respectively. In the 6–10 years age stratum, pain was
the most frequently reported solicited local symptom, which
was reported in 65/148 children (43.9 %) in the ACWY-TT
group and 27/50 children (54.0 %) in the MenC-CRM group
(Fig. 3b). Redness was the most common grade 3 solicited
symptom and was reported in 9/148 children (6.1 %) and 5/
50 children (10.0 %) in the ACWY-TT and the MenC-CRM
groups, respectively.
In the 2–5 years age stratum, the most common solicited
general symptoms reported during the 4-day post-
vaccination follow-up period were irritability in the









Fig. 1 Participant flow. ACWY-
TT group of children who
received one dose of
MenACWY-TT at month 0,
MenC-CRM group of children
who received one dose of
MenC-CRM197 at month 0,
ATP according to protocol, TVC
total vaccinated cohort, N num-
ber of children
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and drowsiness in the MenC-CRM group (each in 6/53
children [11.3 %]) (Fig. 3a). In the 6–10 years age stratum,
fatigue was the most frequently reported solicited general
symptom in both groups and was reported in 33/148 chil-
dren (22.3 %) and 11/50 children (22.0 %) in the ACWY-TT
and the MenC-CRM groups, respectively (Fig. 3b). Head-
ache was the second most frequently reported solicited
general symptom in the ACWY-TT group (30/148 children
[20.3 %]), while it was only reported in 4/50 children
(8.0 %) in the MenC-CRM group. Grade 3 general symp-
toms were uncommonly reported in both treatments groups
(between 0 and 2.7 % of the children across both age strata)
(Fig. 3a, b). No children in either group had fever with grade
3 intensity (oral temperature >39.5 °C).
For the two age strata combined, unsolicited AEs were
reported during the 31-day post-vaccination period in 55/
311 children (17.7 %) and 20/103 children (19.4 %) in the
ACWY-TT and the MenC-CRM groups, respectively. The
most frequently reported unsolicited symptoms were fever
in the ACWY-TT group (8/311 children [2.6 %]) and cough
in the MenC-CRM group (3/103 children [2.9 %]). None of
the children reported grade 3 unsolicited symptoms consid-
ered by the investigator to have a causal relationship to
vaccination.
Throughout the entire study, two children reported each
one new onset of chronic illness: one child in the ACWY-TT
group reported chronic otitis media and one child in the
MenC-CRM group reported allergy to arthropod bites.
Rashes were reported in 8/311 children (2.6 %) in the
ACWY-TT group and 1/103 child (1.0 %) in the MenC-
CRM group and included dermatitis, eczema, rashes and
skin exfoliation. One child in the ACWY-TT group reported
Table 2 Difference between the ACWY-TT and the MenC-CRM groups in percentage of children with an rSBA vaccine response against the four
serogroups at month 1 (ATP cohort for immunogenicity)
Antibody ACWY-TT MenC-CRM Difference in vaccine response rate (ACWY-TT minus MenC-CRM)
N % N % % [95 % CI]
rSBA-MenA 226 94.7 67 11.9 82.75 [72.43–89.23]
rSBA-MenC 268 94.8 92 95.7 −0.88 [−5.25a–5.75]
rSBA-MenW-135 282 98.6 90 12.2 86.36 [77.88–91.80]
rSBA-MenY 285 96.5 88 8.0 88.54 [80.69–93.12]
ACWY-TT group of children who received one dose of MenACWY-TT at month 0,MenC-CRM group of children who received one dose of MenC-
CRM197 at month 0, N number of children with pre- and post-vaccination results available,% percentage of children with a vaccine response, 95 %
CI standardised asymptotic 95 % confidence interval
a The lower limit of the 95 % CI on the difference between groups for MenC was above the pre-specified non-inferiority limit of −10 %
Table 1 Summary of demographic characteristics (total vaccinated cohort)
Characteristic ACWY-TT MenC-CRM
2–5 years 6–10 years 2–5 years 6–10 years
N 163 148 53 50
Age (years) Mean (SD) 3.5 (1.12) 7.9 (1.34) 3.6 (0.95) 7.6 (1.26)
Range 2–5 6–10 2–5 6–10
Sex Female n (%) 80 (49.1) 83 (56.1) 27 (50.9) 24 (48.0)
Male n (%) 83 (50.9) 65 (43.9) 26 (49.1) 26 (52.0)
Race White—Caucasian/European heritage n (%) 145 (89.0) 122 (82.4) 45 (84.9) 42 (84.0)
White—Arabic/North African heritage n (%) 5 (3.1) 11 (7.4) 3 (5.7) 3 (6.0)
African heritage/African American n (%) 6 (3.7) 7 (4.7) 3 (5.7) 3 (6.0)
Asian—South East Asian heritage n (%) 3 (1.8) 0 (0.0) 0 (0.0) 1 (2.0)
Asian—East Asian heritage n (%) 0 (0.0) 2 (1.4) 1 (1.9) 0 (0.0)
Asian—Central/South Asian heritage n (%) 1 (0.6) 0 (0.0) 0 (0.0) 0 (0.0)
Asian—Japanese heritage n (%) 0 (0.0) 1 (0.7) 0 (0.0) 0 (0.0)
Other n (%) 3 (1.8) 5 (3.4) 1 (1.9) 1 (2.0)
ACWY-TT group of children who received one dose of MenACWY-TT at month 0,MenC-CRM group of children who received one dose of MenC-
CRM197 at month 0, N number of children, n (%) number (percentage) of children with the specified characteristic, SD standard deviation
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urticaria 67 days post-vaccination, which resolved without
sequelae and was not considered related to vaccination. AEs
resulting in emergency room visit were reported in 11/311
(3.5 %) children in the ACWY-TT group and 1/103 child
(1.0 %) in the MenC-CRM group.
Throughout the study, SAEs were observed in 6/311
children (1.9 %) who received MenACWY-TT: 4/163 chil-
dren (2.5 %) in the 2–5 age stratum (convulsion, gastro-
esophageal reflux disease and nasopharyngitis, accidental
poisoning and head injury) and 2/148 children (1.4 %) in
the 6–10 age stratum (abdominal injury and appendicitis).
One child (1.0 %) who received MenC-CRM197 (2–5 age
stratum) reported one SAE (gastroenteritis). No SAEs were
considered related to vaccination.
Discussion
In the Netherlands and Canada (Quebec), vaccination with a
single dose of a monovalent conjugate vaccine against
MenC given in the second year of life has resulted in a
decrease of the incidence of diseases caused by this
serogroup [14, 29, 54]. However, protection against the
other major meningococcal serogroups is also needed, es-
pecially for travellers to areas of high endemicity. Currently,
two quadrivalent meningococcal conjugate vaccines have
been licensed in Europe: the MenACWY-CRM197 vaccine
for immunisation of children 2 years of age and older and
the MenACWY-TT vaccine that extends protection to in-
clude toddlers in the second year of life, an age group at
high risk for meningococcal disease. The present study was
primarily designed to demonstrate the non-inferiority of
MenACWY-TT versus MenC-CRM197 in terms of immune
response to MenC in children 2–10 years of age. In addition,
the immunogenicity to MenA, MenW-135 and MenY, and
the safety profile of MenACWY-TT were assessed.
The primary objective of the study was met, and the im-
munogenicity of a single dose of MenACWY-TT was shown
to be non-inferior to that of MenC-CRM197 in terms of rSBA-
MenC vaccine response. However, exploratory analyses sug-
gested that lower rSBA-MenC GMTs were measured after
vaccination with MenACWY-TT compared with MenC-
CRM197. A similar finding was noted in a previous study
conducted in infants showing that rSBA-MenC GMTs in-
duced by the licensed MenACWY-CRM197 vaccine were
lower than those induced by MenC-CRM197 [46]. These
findings could be related to the differences in MenC capsular
polysaccharide doses in MenACWY-TT or MenACWY-
CRM197 (5 μg) as opposed to MenC-CRM197 (10 μg). Fur-
thermore, the additional serogroups included in the quadriva-
lent vaccines compared to the monovalent vaccine may result
in lower overall titres for MenC. Finally, it should be noted
that, in contrast with MenACWY-TT and MenACWY-
CRM197, MenC-CRM197 contains an aluminium adjuvant.
Results of our study are in contrast with those of other
trials in which MenACWY-TT was compared to another
Table 3 Percentage of children
with rSBA titres equal to or
above 1:8 and 1:128 and rSBA
GMTs against the four
serogroups at different time-
points (ATP cohort for
immunogenicity)
ACWY-TT group of children who
received one dose of
MenACWY-TT at month 0,
MenC-CRM group of children
who received one dose of
MenC-CRM197 at month 0, N
number of children with avail-
able results, % percentage of
children with titres within the
specified range, GMT geometric
mean titre, 95 % CI 95 % confi-
dence interval, Pre pre-
vaccination at month 0, Post
post-vaccination at month 1
Group Timing N % ≥1:8 [95 % CI] % ≥1:128 [95 % CI] GMT [95 % CI]
rSBA-MenA
ACWY-TT Pre 227 46.7 [40.1–53.4] 40.5 [34.1–47.2] 31.5 [23.3–42.5]
Post 294 99.7 [98.1–100] 99.7 [98.1–100] 6236.1 [5574.5–6976.3]
MenC-CRM Pre 76 43.4 [32.1–55.3] 36.8 [26.1–48.7] 25.9 [15.6–43.0]
Post 82 41.5 [30.7–52.9] 32.9 [22.9–44.2] 27.2 [15.6–47.4]
rSBA-MenC
ACWY-TT Pre 270 48.5 [42.4–54.7] 23.7 [18.8–29.2] 22.7 [18.1–28.4]
Post 293 100 [98.7–100] 99.3 [97.6–99.9] 2794.8 [2393.5–3263.3]
MenC-CRM Pre 94 46.8 [36.4–57.4] 19.1 [11.8–28.6] 19.4 [13.1–28.8]
Post 97 100 [96.3–100] 100 [96.3–100] 5291.6 [3814.6–7340.5]
rSBA-MenW-135
ACWY-TT Pre 282 80.1 [75.0–84.6] 52.5 [46.5–58.4] 83.2 [67.9–102.0]
Post 296 99.7 [98.1–100] 99.3 [97.6–99.9] 8549.5 [7618.5–9594.3]
MenC-CRM Pre 92 78.3 [68.4–86.2] 46.7 [36.3–57.4] 70.2 [48.5–101.6]
Post 95 80.0 [70.5–87.5] 47.4 [37.0–57.9] 87.3 [58.5–130.4]
rSBA-MenY
ACWY-TT Pre 285 86.3 [81.8–90.1] 67.7 [62.0–73.1] 153.6 [125.3–188.3]
Post 295 100 [98.8–100] 100 [98.8–100] 8360.7 [7447.3–9386.1]
MenC-CRM Pre 90 81.1 [71.5–88.6] 56.7 [45.8–67.1] 107.4 [71.4–161.6]
Post 95 81.1 [71.7–88.4] 58.9 [48.4–68.9] 128.2 [83.8–196.2]
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monovalent MenC-CRM197 vaccine (Meningitec™; Pfizer,
formerly Wyeth) [32, 58]. In these trials, MenACWY-TT
was shown to induce higher rSBA-MenC GMTs than the
monovalent MenC-CRM197 vaccine in toddlers. This differ-
ence is consistent with results of other studies showing that
the immune response induced by MenC-CRM197 (Menju-
gate™) was higher than that induced by the other monova-
lent MenC-CRM197 vaccine (Meningitec™) [44, 47].
The lower rSBA-MenC GMTs induced byMenACWY-TT
compared to MenC-CRM197 in the present study are of un-
known clinical significance, since >99 % of children had
rSBA-MenC titres ≥1:128 at 1 month post-vaccination, sug-
gesting that MenACWY-TT induced seroprotective antibody
titres against MenC in the vast majority of the vaccine
recipients. However, the lower rSBA-MenC GMTs may have
an impact on antibody persistence and this is being explored in
an ongoing extension study (NCT01266993). The persistence
of antibodies in the serum is particularly important for pre-
venting diseases that have a short incubation period, such as
meningococcal diseases, for which the memory B-cell
responses are not sufficiently rapid to prevent bacterial dis-
semination [3, 42]. The lower rSBA-MenC GMTs must be
considered in light of the additional robust responses to
MenA, MenW-135 and MenY induced by MenACWY-TT,
which indicate broader serogroup coverage than that induced
by the monovalent MenC conjugate vaccine.
Currently, there is no international consensus on whether
rabbit (rSBA) or human (hSBA) complement source should
a b
c d
Fig. 2 Reverse cumulative curves for the ACWY-TT and MenC-CRM
groups for rSBA-MenA (a), rSBA-MenC (b), rSBA-MenW-135 (c)
and rSBA-MenY (d) (ATP cohort for immunogenicity). ACWY-TT
group of children who received one dose of MenACWY-TT at month
0, MenCCRM group of children who received one dose of MenC-
CRM197 at month 0. PRE pre-vaccination at month 0, PI(M1) post-
vaccination at month 1
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be considered as standard for bactericidal activity measure-
ments [21, 28, 59]. Although the original correlate of pro-
tection was defined in terms of hSBA titres [20], it was
previously suggested that hSBA assays may have reduced
sensitivity and that while hSBA titres ≥1:4 are predictive of
protection, hSBA titres <1:4 may not necessarily predict
susceptibility [8, 21, 28]. Therefore, a functional assay using
rabbit complement was used to evaluate the immunogenic-
ity of the meningococcal vaccines in the present study.
Moreover, three monovalent MenC vaccines were licensed
in Europe based on rSBA-MenC responses, and during post-
licensure surveillance, rSBA titres of 1:8 were confirmed as
the antibody threshold that best correlated to vaccine effec-
tiveness [1].
The safety profile of MenACWY-TT observed in our
study was in line with that observed in a previous study
conducted in young children in Europe [32]. However,
solicited local symptoms seemed to be more frequently
reported here than in another previous study conducted in
children 2–10 years of age in the Philippines, India, Leb-
anon and Saudi Arabia [37]. The differences between the
safety profiles may reflect differences between the popula-
tions in which the vaccine was studied, both in terms of
biological reactogenicity to the vaccine and cultural differ-
ences in AE reporting.
The present study was limited by its open design, which
had the potential to bias the safety reporting by the investi-
gators and parents/guardians. However, since it is most likely
that bias would be in favour of the control monovalent vaccine
versus the quadrivalent vaccine, the results of the safety com-
parison remain relevant. The study was also potentially limit-
ed by the lack of MenC-TT or quadrivalent meningococcal
a
b
Fig. 3 Percentage of children
in the 2–5 years age stratum (a)
and in the 6–10 years age
stratum (b) experiencing
solicited local and general
symptoms within the 4-day
post-vaccination period (total
vaccinated cohort). ACWY-TT
group of children who received
one dose of MenACWY-TT at
month 0, MenC-CRM group of
children who received one dose
of MenC-CRM197 at month 0.
Error bars represent 95 % con-
fidence intervals
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conjugate vaccines as control and the numerous exploratory
statistical comparisons without multiplicity adjustment, which
should be interpreted with caution.
The results of the present study suggest that
MenACWY-TT has a clinically acceptable safety profile
and the potential to offer protection against meningococ-
cal disease to European children 2–10 years of age, since
the vaccine was shown to provide protection against
additional serogroups while maintaining protection against
serogroup C.
Menactra is a trademark of Sanofi Pasteur.
Menveo and Menjugate are trademarks of Novartis Vac-
cines and Diagnostics, Inc.
Meningitec is a trademark of Pfizer, formerly Wyeth.
Nimenrix is a trademark of the GlaxoSmithKline Group
of companies.
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